TY - JOUR
T1 - Metabolic Syndrome and psoriatic arthritis
T2 - considerations for the clinician
AU - Caso, Francesco
AU - Chimenti, Maria Sole
AU - Navarini, Luca
AU - Ruscitti, Piero
AU - Peluso, Rosario
AU - Girolimetto, Nicolò
AU - Del Puente, Antonio
AU - Giacomelli, Roberto
AU - Scarpa, Raffaele
AU - Costa, Luisa
PY - 2020/4
Y1 - 2020/4
N2 - Introduction: Metabolic Syndrome (MetS) is strictly interconnected with systemic inflammation, and increased evidence has described a close link between this condition and Psoriatic Arthritis (PsA).Areas covered: This review summarizes main studies exploring clinical aspects and prevalence of MetS in PsA cohorts. Further, there is accumulating evidence showing shared inflammatory pathways between MetS, its components, and PsA.Expert opinion: The high prevalence of MetS in PsA highlights the need for screening, evaluation, and close monitoring of MetS and its components (namely, diabetes mellitus, obesity, hypertension, and dyslipidemia) in psoriatic patients.Further studies should focus on the pathogenetic link between MetS and PsA. More studies are required to identify appropriate algorithms for the assessment and management of MetS in PsA patients.
AB - Introduction: Metabolic Syndrome (MetS) is strictly interconnected with systemic inflammation, and increased evidence has described a close link between this condition and Psoriatic Arthritis (PsA).Areas covered: This review summarizes main studies exploring clinical aspects and prevalence of MetS in PsA cohorts. Further, there is accumulating evidence showing shared inflammatory pathways between MetS, its components, and PsA.Expert opinion: The high prevalence of MetS in PsA highlights the need for screening, evaluation, and close monitoring of MetS and its components (namely, diabetes mellitus, obesity, hypertension, and dyslipidemia) in psoriatic patients.Further studies should focus on the pathogenetic link between MetS and PsA. More studies are required to identify appropriate algorithms for the assessment and management of MetS in PsA patients.
U2 - 10.1080/1744666X.2020.1740593
DO - 10.1080/1744666X.2020.1740593
M3 - Article
C2 - 32149545
VL - 16
SP - 409
EP - 420
JO - Expert Review of Clinical Immunology
JF - Expert Review of Clinical Immunology
SN - 1744-666X
IS - 4
ER -